Aarkstore -Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore -Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0f12-ZGU1N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore -Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014

Description:

DelveInsights, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). – PowerPoint PPT presentation

Number of Views:48

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore -Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Pipeline Insights, 2014


1
Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia)-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/77056/-familia
    l-hypercholesterolemia-type-ii-hyperlipoproteinemi
    a-pipeline-insights-2014

2
Summary
  • DelveInsights, Familial Hypercholesterolemia
    (Type II Hyperlipoproteinemia)-Pipeline Insights,
    2014, report provides comprehensive insights
    about pipeline drugs across this indication. A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia). This report provides
    information on the therapeutic development based
    on the Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) dealing with all the
    pipeline drugs, comparative analysis at various
    stages covering Filed, Phase III, Phase II, Phase
    I, IND filed, Preclinical, Discovery and unknown
    stages, therapeutics assessment by monotherapy
    and combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Note This report requires
    certain updates. We have all the information
    available but require 3 business days to complete
    the process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated Indication.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    )The report provides pipeline products under
    drug profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    typeThe report reviews key players involved in
    the therapeutics development for Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) and also provide company profilingThe report
    also gives the information of dormant and
    discontinued pipeline projects Pipeline products
    coverage based on various stages of development
    ranging from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete Pipeline intelligence
    and complete understanding over therapeutics
    development for Familial Hypercholesterolemia
    (Type II Hyperlipoproteinemia)Identify the
    relationship between the drugs and use it for
    target finding, drug repurposing, and precision
    medicine.Devise corrective measures for pipeline
    projects by understanding Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) pipeline depth and focus of Indication
    therapeutics Developing strategic initiatives to
    support your drug development activities.Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and ScopeProvides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipelineGaining a Full Picture of the
    Competitive Landscape for Evidence based
    Decisions

7
Table of Content
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) OverviewFamilial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Pipeline TherapeuticsFamilial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Therapeutics under Development by
    Companies Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Late Stage Products (Filed
    and Phase III)Comparative Analysis Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Mid Clinical Stage Products (Phase
    II)Comparative Analysis Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Early Clinical Stage Products (Phase I and IND
    Filed)Comparative Analysis Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Discovery and Pre-Clinical Stage
    Products Comparative Analysis Drug Candidate
    Profiles

8
Table of Content
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Therapeutics
    Assessment Assessment by Monotherapy
    Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Discontinued
    Products Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Dormant ProductsCompanies
    Involved in Therapeutics Development for Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Appendix Methodology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ), 2014Number of Products under Development by
    Companies Comparative Analysis by Late Clinical
    Stage Products (Filed and Phase III),
    2014Comparative Analysis Mid Clinical Stage
    Products (Phase II), 2014Comparative Analysis
    Early Clinical Stage Products (Phase I and IND
    Filed), 2014Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014Drug Candidates
    ProfilesFamilial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Assessment by Monotherapy
    Products Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Assessment by Combination
    Products Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Assessment by Route of
    Administration 

10
List of Tables
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia) Assessment by Stage and
    Route of Administration Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Molecule Type Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Stage and Molecule Type Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Therapeutics Discontinued Products Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Therapeutics Dormant ProductsProducts under
    Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ), 2014Late Clinical Stage Products (Filed and
    Phase III), 2014Mid Clinical Stage Products
    (Phase II), 2014Early Clinical Stage Products
    (Phase I and IND Filed), 2014Discovery and
    Pre-Clinical Stage Products, 2014Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Monotherapy Products Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Combination Products Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Route of Administration Familial
    Hypercholesterolemia (Type II Hyperlipoproteinemia
    ) Assessment by Stage and Route of
    Administration Familial Hypercholesterolemia
    (Type II Hyperlipoproteinemia) Assessment by
    Molecule Type Familial Hypercholesterolemia
    (Type II Hyperlipoproteinemia) Assessment by
    Stage and Molecule Type

12
Related Reports
  • The Mobile Healthcare (mHealth) Bible 2014 -
    2020
  • Pregnancy Detection Kit Market in the US
    2015-2019
  • Global Prenatal and Newborn Genetic Testing
    Market 2015-2019
  • Global Knee Implant market 2015-2019
  • Global Isosorbide Market 2015-2019

13
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia)-Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights, Familial Hypercholesterolemia
    (Type II Hyperlipoproteinemia)-Pipeline Insights,
    2014, report provides comprehensive insights
    about pipeline drugs across this indication.
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com